Michael J. Kruhlak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael J. Kruhlak has a total of 289 co-authors. Here are the top co-authors by number of shared publications:
- Andy D. Tran
Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
75 shared publications - Daiki Taniyama
Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
40 shared publications - Yves Pommier
National Cancer Institute 2 Bethesda, Md
40 shared publications - Anjali Dhall
Department of Computational Biology, Indraprastha Institute of Information Technology, Okhla Phase 3, New Delhi 110020, India
39 shared publications - Christophe E. Redon
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
39 shared publications - Liton Kumar Saha
Developmental Therapeutics Branch & Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
39 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10) , e72322
Basal Marker ΔNp63α Is Enriched in Pancreatic Cancer Metastases but Not in Primary Tumors Post‐Chemotherapy
Cancer cells within a single pancreatic ductal adenocarcinoma (PDAC) are most often heterogeneous in their expression of the basal or classical transcriptional program. Predominance of the basal subtype has been associated with poorer patient outcomes and increased resistance to chemotherapy. Based on this, we predicted that basal subtype would be enriched in tumors previously treated with chemotherapy, and in metastases derived from primary PDAC tumors with a mixed basal/classical population. To create matched classical and basal cell lines, we stably transduced two classical PDAC cell lines (AsPC1 and HPAFII) with the basal program transcriptional driver ∆Np63α or an mCherry control and assessed their growth, metastasis, and response to chemotherapy both in vitro and in vivo. Forced expression of ∆Np63α successfully converted both cell lines to basal transcriptomic subtype, yet the basal program failed to drive increased cell growth or chemoresistance in culture and did not affect tumor growth of AsPC1 in the murine pancreas. In mice orthotopically engrafted with ∆Np63α‐expressing cells, no statistically significant increase in spontaneous pulmonary metastases was observed for AsPC1 or HPAFII, however, pulmonary metastases were enriched for ∆Np63 expression as compared to established primary tumors, including expression of endogenous ∆Np63 in the mCherry control. Increased resistance to irinotecan chemotherapy was observed in ∆Np63α + HPAFII, yet treatment selected for ∆Np63‐negative cells in both HPAFII and ASPC1. In summary, our data show that PDAC metastases are enriched for basal subtype, but chemotherapy treatment does not preferentially select for basal‐type cells.
- 14 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10) , e72322
Open AccessBasal Marker ΔNp63α Is Enriched in Pancreatic Cancer Metastases but Not in Primary Tumors Post‐Chemotherapy
Cancer cells within a single pancreatic ductal adenocarcinoma (PDAC) are most often heterogeneous in their expression of the basal or classical transcriptional program. Predominance of the basal subtype has been associated with poorer patient outcomes and increased resistance to chemotherapy. Based on this, we predicted that basal subtype would be enriched in tumors previously treated with chemotherapy, and in metastases derived from primary PDAC tumors with a mixed basal/classical population. To create matched classical and basal cell lines, we stably transduced two classical PDAC cell lines (AsPC1 and HPAFII) with the basal program transcriptional driver ∆Np63α or an mCherry control and assessed their growth, metastasis, and response to chemotherapy both in vitro and in vivo. Forced expression of ∆Np63α successfully converted both cell lines to basal transcriptomic subtype, yet the basal program failed to drive increased cell growth or chemoresistance in culture and did not affect tumor growth of AsPC1 in the murine pancreas. In mice orthotopically engrafted with ∆Np63α‐expressing cells, no statistically significant increase in spontaneous pulmonary metastases was observed for AsPC1 or HPAFII, however, pulmonary metastases were enriched for ∆Np63 expression as compared to established primary tumors, including expression of endogenous ∆Np63 in the mCherry control. Increased resistance to irinotecan chemotherapy was observed in ∆Np63α + HPAFII, yet treatment selected for ∆Np63‐negative cells in both HPAFII and ASPC1. In summary, our data show that PDAC metastases are enriched for basal subtype, but chemotherapy treatment does not preferentially select for basal‐type cells.
- Open Access
- 5 October 2026
- Published by Springer Nature in Cell Death & Disease
Ceramide stress defines a targetable metabolic vulnerability in IDH1-mutant oligodendroglioma
Oligodendroglioma is genetically defined by mutations in isocitrate dehydrogenase 1 or 2 (IDH1/IDH2) and 1p/19q codeletion. These tumors exhibit a distinct metabolic state driven by the oncometabolite D-2-hydroxyglutarate, which shifts the sphingosine-1-phosphate–ceramide rheostat toward ceramide accumulation. Taking advantage of this intrinsic metabolic state, we investigated whether further elevating ceramide levels through inhibition of acid ceramidase—a key enzyme that degrades ceramide to sphingosine—could promote apoptotic cell death. Analysis of patient datasets demonstrated that acid ceramidase is expressed at higher levels in both low- and high-grade gliomas compared with normal tissue. Treatment with SABRAC, a small-molecule inhibitor of acid ceramidase, robustly reduced viability in IDH1-mutant oligodendroglioma cell lines and induced rapid, marked accumulation of multiple ceramide species with coordinated sphingolipid remodeling. Subcellular imaging using a fluorescent ceramide analogue revealed increased ceramide localization to lysosomes and mitochondria following SABRAC treatment. This was associated with cytochrome c redistribution, executioner caspase activation, and apoptotic cell death, consistent with engagement of the intrinsic mitochondrial pathway. Transcriptomic and biochemical analyses further demonstrated activation of endoplasmic reticulum stress and unfolded protein response signaling, including PERK- and IRE1α-associated programs, indicating a coordinated multi-organelle stress response to sustained ceramide elevation. These mechanistic effects translated into prolonged survival in oligodendroglioma xenograft-bearing mice. Together, these findings suggest that IDH1-mutant oligodendroglioma harbors a heightened sensitivity to ceramide stress and identify ceramide accumulation as a therapeutically actionable metabolic vulnerability.
- 5 October 2026
- Published by Springer Nature in Cell Death & Disease
Open AccessCeramide stress defines a targetable metabolic vulnerability in IDH1-mutant oligodendroglioma
Oligodendroglioma is genetically defined by mutations in isocitrate dehydrogenase 1 or 2 (IDH1/IDH2) and 1p/19q codeletion. These tumors exhibit a distinct metabolic state driven by the oncometabolite D-2-hydroxyglutarate, which shifts the sphingosine-1-phosphate–ceramide rheostat toward ceramide accumulation. Taking advantage of this intrinsic metabolic state, we investigated whether further elevating ceramide levels through inhibition of acid ceramidase—a key enzyme that degrades ceramide to sphingosine—could promote apoptotic cell death. Analysis of patient datasets demonstrated that acid ceramidase is expressed at higher levels in both low- and high-grade gliomas compared with normal tissue. Treatment with SABRAC, a small-molecule inhibitor of acid ceramidase, robustly reduced viability in IDH1-mutant oligodendroglioma cell lines and induced rapid, marked accumulation of multiple ceramide species with coordinated sphingolipid remodeling. Subcellular imaging using a fluorescent ceramide analogue revealed increased ceramide localization to lysosomes and mitochondria following SABRAC treatment. This was associated with cytochrome c redistribution, executioner caspase activation, and apoptotic cell death, consistent with engagement of the intrinsic mitochondrial pathway. Transcriptomic and biochemical analyses further demonstrated activation of endoplasmic reticulum stress and unfolded protein response signaling, including PERK- and IRE1α-associated programs, indicating a coordinated multi-organelle stress response to sustained ceramide elevation. These mechanistic effects translated into prolonged survival in oligodendroglioma xenograft-bearing mice. Together, these findings suggest that IDH1-mutant oligodendroglioma harbors a heightened sensitivity to ceramide stress and identify ceramide accumulation as a therapeutically actionable metabolic vulnerability.
- 25 September 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF15
Targeting Mitochondrial Protease in Diffuse Gliomas
Caseinolytic protease proteolytic subunit (ClpP) is part of the mitochondrial ClpXP protease responsible for degrading damaged proteins in the matrix, thus maintaining metabolic homeostasis. Small molecule activators of ClpP (ClpP agonists) have recently shown great promise against metabolically active cancers. TR107, a novel ClpP activator, demonstrates potent and selective cytotoxicity against glioma cells at nanomolar concentrations. Compared with the FDA-approved ClpP agonist ONC201 (dordaviprone), TR107 shows greater efficacy across patient-derived and isogenic glioma models. TR107 effects are ClpP-dependent and result in widespread mitochondrial dysfunction evident by extensive protein degradation, impaired oxidative phosphorylation, reduced mitochondrial DNA copy number, and ATP depletion. These disruptions are more severe in isocitrate dehydrogenase (IDH)-mutant than in IDH wild-type glioma cells, leading to enhanced cell-cycle arrest, apoptosis, and inhibition of the mTOR/AKT/4EBP1 signaling pathway. In this study, we show that ClpP agonism demonstrates preferential antitumor activity against IDH-mutant glioma in in vitro, ex vivo, and in vivo models. These findings support TR107 as a promising new targeted therapeutic for IDH-mutant gliomas.
- 25 September 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF15
Targeting Mitochondrial Protease in Diffuse Gliomas
Caseinolytic protease proteolytic subunit (ClpP) is part of the mitochondrial ClpXP protease responsible for degrading damaged proteins in the matrix, thus maintaining metabolic homeostasis. Small molecule activators of ClpP (ClpP agonists) have recently shown great promise against metabolically active cancers. TR107, a novel ClpP activator, demonstrates potent and selective cytotoxicity against glioma cells at nanomolar concentrations. Compared with the FDA-approved ClpP agonist ONC201 (dordaviprone), TR107 shows greater efficacy across patient-derived and isogenic glioma models. TR107 effects are ClpP-dependent and result in widespread mitochondrial dysfunction evident by extensive protein degradation, impaired oxidative phosphorylation, reduced mitochondrial DNA copy number, and ATP depletion. These disruptions are more severe in isocitrate dehydrogenase (IDH)-mutant than in IDH wild-type glioma cells, leading to enhanced cell-cycle arrest, apoptosis, and inhibition of the mTOR/AKT/4EBP1 signaling pathway. In this study, we show that ClpP agonism demonstrates preferential antitumor activity against IDH-mutant glioma in in vitro, ex vivo, and in vivo models. These findings support TR107 as a promising new targeted therapeutic for IDH-mutant gliomas.
- Open Access
Deep vein thrombosis-primed neutrophils reshape the brain microenvironment to promote brain metastasis
Brain metastasis (BrM) is a devastating complication of triple-negative breast cancer (TNBC), yet how host macroenvironmental conditions influence brain metastatic susceptibility remains poorly understood. Here, we investigated the impact of deep vein thrombosis (DVT), a common complication in patients with cancer, on TNBC brain metastasis. Analysis of a large clinical cohort identified DVT as an independent risk factor for BrM in patients with metastatic breast cancer. Using two syngeneic TNBC models, we demonstrated that DVT selectively enhanced brain metastasis without significantly affecting primary tumor growth or lung metastasis. Mechanistically, DVT increased neutrophil accumulation in the brain metastatic microenvironment, and neutrophil depletion completely abrogated the metastasis-promoting effect of DVT. Single-cell RNA sequencing of CD45+ cells in peripheral blood revealed that DVT reprogrammed circulating neutrophils toward migratory and inflammatory transcriptomic profiles characterized by neutrophil extracellular trap (NET) formation. DVT increased CXCR2 expression on circulating neutrophils and enhanced neutrophil recruitment in brain. Moreover, DVT significantly increased circulating NETs. Collectively, our findings identify DVT as a systemic driver of TNBC brain metastasis and reveal that DVT primes circulating neutrophils toward enhanced vascular recruitment and NET formation, providing a mechanistic link between cancer-associated thrombosis and brain metastatic susceptibility.
Open AccessDeep vein thrombosis-primed neutrophils reshape the brain microenvironment to promote brain metastasis
Brain metastasis (BrM) is a devastating complication of triple-negative breast cancer (TNBC), yet how host macroenvironmental conditions influence brain metastatic susceptibility remains poorly understood. Here, we investigated the impact of deep vein thrombosis (DVT), a common complication in patients with cancer, on TNBC brain metastasis. Analysis of a large clinical cohort identified DVT as an independent risk factor for BrM in patients with metastatic breast cancer. Using two syngeneic TNBC models, we demonstrated that DVT selectively enhanced brain metastasis without significantly affecting primary tumor growth or lung metastasis. Mechanistically, DVT increased neutrophil accumulation in the brain metastatic microenvironment, and neutrophil depletion completely abrogated the metastasis-promoting effect of DVT. Single-cell RNA sequencing of CD45+ cells in peripheral blood revealed that DVT reprogrammed circulating neutrophils toward migratory and inflammatory transcriptomic profiles characterized by neutrophil extracellular trap (NET) formation. DVT increased CXCR2 expression on circulating neutrophils and enhanced neutrophil recruitment in brain. Moreover, DVT significantly increased circulating NETs. Collectively, our findings identify DVT as a systemic driver of TNBC brain metastasis and reveal that DVT primes circulating neutrophils toward enhanced vascular recruitment and NET formation, providing a mechanistic link between cancer-associated thrombosis and brain metastatic susceptibility.
- Open Access
- 14 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF19
Epigenetic Repression of Type I Interferon Signaling by RUNX2 Drives Immune Checkpoint Blockade Resistance in Osteosarcoma
Interferon (IFN) signaling plays a pivotal role in orchestrating antitumor immunity and shaping the response to immune checkpoint blockade (ICB). Although genetic alterations that impair the IFN pathway have been reported, such events are relatively rare, suggesting a potential contribution of epigenetic dysregulation. In this study, we identified a runt-related transcription factor 2 (RUNX2)–mediated epigenetic mechanism that disrupts the type I IFN (IFN-I) signaling pathway in osteosarcoma, thereby limiting the efficacy of ICB. The development of an algorithm to assess the association of 1,425 transcription factors with IFN pathway activation in human osteosarcoma tumors enabled the identification of RUNX2 as a potential negative regulator of IFN signaling. RUNX2 depletion in osteosarcoma cells activated the IFNB1-driven IFN-I response. Mechanistically, RUNX2 formed a transcriptional repressor complex with nuclear receptor corepressor 1 (NCOR1) and histone deacetylase 3 (HDAC3) that reduced H3K9 acetylation at the enhancers of key IFN-I genes, leading to their downregulation. Inhibition of the RUNX2–NCOR1–HDAC3 complex enhanced IFN-I signaling, with cyclic GMP–AMP synthase (cGAS), stimulator of IFN genes (STING), and IFNB1 being required for the induction of IFN-stimulated genes and tumor suppression. Paradoxically, reactivation of IFN-I signaling also upregulated immune checkpoint molecules PD-L1 and PD-L2. Combination treatment with a selective HDAC3 inhibitor and anti–PD-1 antibody led to durable tumor regression in syngeneic osteosarcoma mouse models, accompanied by increased cytotoxic T-cell infiltration. These findings reveal a mechanistic link between RUNX2-driven epigenetic repression and impaired antitumor immunity via the cGAS–STING–IFN-I axis and suggest a rational combinatorial strategy to overcome osteosarcoma resistance to ICB. Significance: Targeting HDAC3 overcomes immune escape driven by epigenetic repression of IFN-I signaling by the RUNX2–NCOR1–HDAC3 pathway and enhances anti-PD-1 sensitivity in osteosarcoma, providing a potential therapeutic strategy for immunotherapy-resistant tumors.
- 14 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF19
Open AccessEpigenetic Repression of Type I Interferon Signaling by RUNX2 Drives Immune Checkpoint Blockade Resistance in Osteosarcoma
Interferon (IFN) signaling plays a pivotal role in orchestrating antitumor immunity and shaping the response to immune checkpoint blockade (ICB). Although genetic alterations that impair the IFN pathway have been reported, such events are relatively rare, suggesting a potential contribution of epigenetic dysregulation. In this study, we identified a runt-related transcription factor 2 (RUNX2)–mediated epigenetic mechanism that disrupts the type I IFN (IFN-I) signaling pathway in osteosarcoma, thereby limiting the efficacy of ICB. The development of an algorithm to assess the association of 1,425 transcription factors with IFN pathway activation in human osteosarcoma tumors enabled the identification of RUNX2 as a potential negative regulator of IFN signaling. RUNX2 depletion in osteosarcoma cells activated the IFNB1-driven IFN-I response. Mechanistically, RUNX2 formed a transcriptional repressor complex with nuclear receptor corepressor 1 (NCOR1) and histone deacetylase 3 (HDAC3) that reduced H3K9 acetylation at the enhancers of key IFN-I genes, leading to their downregulation. Inhibition of the RUNX2–NCOR1–HDAC3 complex enhanced IFN-I signaling, with cyclic GMP–AMP synthase (cGAS), stimulator of IFN genes (STING), and IFNB1 being required for the induction of IFN-stimulated genes and tumor suppression. Paradoxically, reactivation of IFN-I signaling also upregulated immune checkpoint molecules PD-L1 and PD-L2. Combination treatment with a selective HDAC3 inhibitor and anti–PD-1 antibody led to durable tumor regression in syngeneic osteosarcoma mouse models, accompanied by increased cytotoxic T-cell infiltration. These findings reveal a mechanistic link between RUNX2-driven epigenetic repression and impaired antitumor immunity via the cGAS–STING–IFN-I axis and suggest a rational combinatorial strategy to overcome osteosarcoma resistance to ICB. Significance: Targeting HDAC3 overcomes immune escape driven by epigenetic repression of IFN-I signaling by the RUNX2–NCOR1–HDAC3 pathway and enhances anti-PD-1 sensitivity in osteosarcoma, providing a potential therapeutic strategy for immunotherapy-resistant tumors.
- Open Access
- 11 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (37)
Peroxiredoxin 1 safeguards the nucleolar genome from oxidative damage
Peroxiredoxin 1 (PRDX1) is a highly conserved, thiol-dependent peroxidase that rapidly scavenges reactive oxygen species to modulate redox signaling. PRDX1-null mice exhibited genomic instability, shortened life span, and accelerated tumorigenesis, including development of lymphomas, sarcomas, and carcinomas. Despite extensive characterization of these phenotypes, the molecular mechanism by which PRDX1 loss causes genomic instability remains poorly understood. Here, we show that PRDX1 deficiency alters nucleolar morphology, impairs RNA polymerase I (POL-I)–dependent transcription of pre–ribosomal RNAs, and triggers nucleolar genomic instability. This oxidative stress–induced nucleolar dysfunction promotes the stability of secondary DNA structures, such as RNA-DNA hybrids and G-quadruplex DNA, contributing to nucleolar genomic instability. We demonstrate that PRDX1 loss reduces nascent ribosomal RNA (rRNA) levels and impairs rRNA processing, further affecting ribosome biogenesis. Mechanistically, we established that PRDX1 loss triggers activation of the nucleolar DNA damage response characterized by activation of the DNA repair kinase ATM and elevated TCOF1 within the nucleolus. In addition, we observed recruitment of the MRE11-RAD50-NBS1 (MRN) complex subunit NBS1 to ribosomal DNA (rDNA) loci and this was further increased under oxidative stress. NBS1 accumulation correlates with the repression of rDNA transcription by POL-I, potentially delaying rRNA synthesis, and safeguarding the nucleolar genome from further oxidative damage. Collectively, these findings uncover a previously unrecognized, but critical role, for PRDX1 in maintaining nucleolar integrity and ribosomal biogenesis through redox-dependent regulation of rDNA transcription and processing machinery.
- 11 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (37)
Open AccessPeroxiredoxin 1 safeguards the nucleolar genome from oxidative damage
Peroxiredoxin 1 (PRDX1) is a highly conserved, thiol-dependent peroxidase that rapidly scavenges reactive oxygen species to modulate redox signaling. PRDX1-null mice exhibited genomic instability, shortened life span, and accelerated tumorigenesis, including development of lymphomas, sarcomas, and carcinomas. Despite extensive characterization of these phenotypes, the molecular mechanism by which PRDX1 loss causes genomic instability remains poorly understood. Here, we show that PRDX1 deficiency alters nucleolar morphology, impairs RNA polymerase I (POL-I)–dependent transcription of pre–ribosomal RNAs, and triggers nucleolar genomic instability. This oxidative stress–induced nucleolar dysfunction promotes the stability of secondary DNA structures, such as RNA-DNA hybrids and G-quadruplex DNA, contributing to nucleolar genomic instability. We demonstrate that PRDX1 loss reduces nascent ribosomal RNA (rRNA) levels and impairs rRNA processing, further affecting ribosome biogenesis. Mechanistically, we established that PRDX1 loss triggers activation of the nucleolar DNA damage response characterized by activation of the DNA repair kinase ATM and elevated TCOF1 within the nucleolus. In addition, we observed recruitment of the MRE11-RAD50-NBS1 (MRN) complex subunit NBS1 to ribosomal DNA (rDNA) loci and this was further increased under oxidative stress. NBS1 accumulation correlates with the repression of rDNA transcription by POL-I, potentially delaying rRNA synthesis, and safeguarding the nucleolar genome from further oxidative damage. Collectively, these findings uncover a previously unrecognized, but critical role, for PRDX1 in maintaining nucleolar integrity and ribosomal biogenesis through redox-dependent regulation of rDNA transcription and processing machinery.
- Open Access
- 9 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Spindle Assembly Checkpoint Competency Determines Sensitivity to KIF18A Inhibition in Small Cell Lung Cancer
Figure S1. Sensitivity analyses evaluating dataset-dependent effects in cross-cohort RNA expression comparisons and KIF18A-associated features in SCLC datasets.
- 9 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Spindle Assembly Checkpoint Competency Determines Sensitivity to KIF18A Inhibition in Small Cell Lung Cancer
Figure S1. Sensitivity analyses evaluating dataset-dependent effects in cross-cohort RNA expression comparisons and KIF18A-associated features in SCLC datasets.
- Open Access
- 9 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Spindle Assembly Checkpoint Competency Determines Sensitivity to KIF18A Inhibition in Small Cell Lung Cancer
Association of KIF18A expression with CIN in SCLC. A, Box plot showing the FGA scores across different lung cancer subtypes, including lung adenocarcinoma (LUAD, n = 518) and LUSC (n = 500) from The Cancer Genome Atlas (TCGA) database (30), and SCLC (n = 58) from George and colleagues (3). B, Box plots showing CES (left; ref. 28) and CIN70 gene signature (right; ref. 29) using TCGA (30) and George and colleagues datasets. C, Box plot showing KIF18A transcript levels across lung cancer subtypes in TCGA and George and colleagues datasets. D, Scatter plots showing the relationship between KIF18A transcript levels and CES (left) and CIN70 (right), across SCLC tumors from the George and colleagues dataset. E, Scatter plots showing correlations between KIF18A expression and proliferation markers PCNA (left) and MKI67 (right) in the George and colleagues dataset. F, Box plots showing KIF18A transcript levels across molecular subtypes of SCLC (ASCL1, NEUROD1, POU2F3, and YAP1) in the George and colleagues dataset. P values in A–C and F were calculated using two-sided Wilcoxon tests. Correlations in D and E were assessed using Spearman rank correlation. ns, not statistically significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. TPM, transcripts per million.
- 9 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Spindle Assembly Checkpoint Competency Determines Sensitivity to KIF18A Inhibition in Small Cell Lung Cancer
Association of KIF18A expression with CIN in SCLC. A, Box plot showing the FGA scores across different lung cancer subtypes, including lung adenocarcinoma (LUAD, n = 518) and LUSC (n = 500) from The Cancer Genome Atlas (TCGA) database (30), and SCLC (n = 58) from George and colleagues (3). B, Box plots showing CES (left; ref. 28) and CIN70 gene signature (right; ref. 29) using TCGA (30) and George and colleagues datasets. C, Box plot showing KIF18A transcript levels across lung cancer subtypes in TCGA and George and colleagues datasets. D, Scatter plots showing the relationship between KIF18A transcript levels and CES (left) and CIN70 (right), across SCLC tumors from the George and colleagues dataset. E, Scatter plots showing correlations between KIF18A expression and proliferation markers PCNA (left) and MKI67 (right) in the George and colleagues dataset. F, Box plots showing KIF18A transcript levels across molecular subtypes of SCLC (ASCL1, NEUROD1, POU2F3, and YAP1) in the George and colleagues dataset. P values in A–C and F were calculated using two-sided Wilcoxon tests. Correlations in D and E were assessed using Spearman rank correlation. ns, not statistically significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. TPM, transcripts per million.
- Open Access
- 9 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Spindle Assembly Checkpoint Competency Determines Sensitivity to KIF18A Inhibition in Small Cell Lung Cancer
Figure S4. Single-cell analysis of mitotic timing and fate following KIF18A inhibition in NCI-H841 cells.
- 9 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Spindle Assembly Checkpoint Competency Determines Sensitivity to KIF18A Inhibition in Small Cell Lung Cancer
Figure S4. Single-cell analysis of mitotic timing and fate following KIF18A inhibition in NCI-H841 cells.
- Open Access
- 9 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Spindle Assembly Checkpoint Competency Determines Sensitivity to KIF18A Inhibition in Small Cell Lung Cancer
Molecular features associated with sensitivity to KIF18A inhibition in SCLC. A, Scatter plot showing the KIF18A mRNA expression and NE status across SCLC cell lines. NE scores were calculated according to Zhang and colleagues (26) using a 50-gene NE signature. Each datapoint represents an individual SCLC cell line. B, Bar graph showing relative KIF18A mRNA levels across SCLC cell lines as measured by quantitative RT-PCR. Expression was normalized to GAPDH. Data represent mean ± SD from three independent biological replicates. C, Western blot analysis of KIF18A protein levels across a panel of SCLC cell lines. α-Tubulin was used as the loading control. Bar graph showing relative KIF18A protein levels across SCLC cell lines as measured by immunoblotting. Protein expression was normalized to α-tubulin. Data represent mean ± SD from three independent biological replicates. D, Dose–response curves showing the sensitivity of SCLC cell lines to a KIF18A inhibitor, generated using technical replicates. Cell lines were grouped by drug response at the highest tested concentration: sensitive if viability was <50%, resistant if viability was ≥85% (Imax_obs < 15%), and partial/excluded if viability remained ≥50% despite measurable inhibition (Imax_obs ≥ 10%–15%). E, Dot plots showing KIF18A transcript levels for individual SCLC cell lines classified as KIF18A inhibitor sensitive or resistant. F, Dot plots showing NE scores for individual SCLC cell lines classified as KIF18A inhibitor sensitive or resistant. G, Dot plots showing KIF18A protein levels for individual SCLC cell lines classified as KIF18A inhibitor sensitive or resistant. H, Summary of GSEA comparing transcriptomic profiles of AM-9022–sensitive (n = 4) vs. –resistant (n = 10) SCLC cell lines. Gene sets with positive normalized enrichment scores (NES; red) are enriched in AM-9022–sensitive SCLC cell lines, whereas gene sets with negative NES (black) are enriched in resistant cell lines and depleted in sensitive cell lines. I, GSEA enrichment score plots showing enrichment of CIN (CES), mitotic spindle, and spindle checkpoint in AM-9022–sensitive SCLC cell lines relative to resistant cell lines. Statistical significance was determined using the Mann–Whitney U test. DN, downregulated; Imax_obs, observed maximum inhibition; Neg, negative; ns, not statistically significant; Pos, positive.
- 9 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Spindle Assembly Checkpoint Competency Determines Sensitivity to KIF18A Inhibition in Small Cell Lung Cancer
Molecular features associated with sensitivity to KIF18A inhibition in SCLC. A, Scatter plot showing the KIF18A mRNA expression and NE status across SCLC cell lines. NE scores were calculated according to Zhang and colleagues (26) using a 50-gene NE signature. Each datapoint represents an individual SCLC cell line. B, Bar graph showing relative KIF18A mRNA levels across SCLC cell lines as measured by quantitative RT-PCR. Expression was normalized to GAPDH. Data represent mean ± SD from three independent biological replicates. C, Western blot analysis of KIF18A protein levels across a panel of SCLC cell lines. α-Tubulin was used as the loading control. Bar graph showing relative KIF18A protein levels across SCLC cell lines as measured by immunoblotting. Protein expression was normalized to α-tubulin. Data represent mean ± SD from three independent biological replicates. D, Dose–response curves showing the sensitivity of SCLC cell lines to a KIF18A inhibitor, generated using technical replicates. Cell lines were grouped by drug response at the highest tested concentration: sensitive if viability was <50%, resistant if viability was ≥85% (Imax_obs < 15%), and partial/excluded if viability remained ≥50% despite measurable inhibition (Imax_obs ≥ 10%–15%). E, Dot plots showing KIF18A transcript levels for individual SCLC cell lines classified as KIF18A inhibitor sensitive or resistant. F, Dot plots showing NE scores for individual SCLC cell lines classified as KIF18A inhibitor sensitive or resistant. G, Dot plots showing KIF18A protein levels for individual SCLC cell lines classified as KIF18A inhibitor sensitive or resistant. H, Summary of GSEA comparing transcriptomic profiles of AM-9022–sensitive (n = 4) vs. –resistant (n = 10) SCLC cell lines. Gene sets with positive normalized enrichment scores (NES; red) are enriched in AM-9022–sensitive SCLC cell lines, whereas gene sets with negative NES (black) are enriched in resistant cell lines and depleted in sensitive cell lines. I, GSEA enrichment score plots showing enrichment of CIN (CES), mitotic spindle, and spindle checkpoint in AM-9022–sensitive SCLC cell lines relative to resistant cell lines. Statistical significance was determined using the Mann–Whitney U test. DN, downregulated; Imax_obs, observed maximum inhibition; Neg, negative; ns, not statistically significant; Pos, positive.